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Abstract
Anticoagulant use, such as heparin, is usu-
ally contraindicated in acute stroke patients.
We present a study of patients, who were treat-
ed with intravenous heparin after a stroke that
were also found to have an intraluminal
thrombus. Prior studies imply that recanaliza-
tion is achieved with heparin; however
heparin should only prevent thrombus propa-
gation. Therefore it is unclear whether and
how IV heparin can achieve recanalization of
intraluminal thrombi in acute stroke patients.
A retrospective review of all acute stroke
patients from a single stroke center who
received a therapeutic IV heparin infusion
from 5/2006 to 9/2011 were included in the
study. We compared patients who had com-
plete/partial recanalization and/or improved
flow versus those that did not, with both these
groups on a standard intravenous heparin
infusion protocol. Demographic data was com-
pared between the groups. Average partial
thromboplastin time (PTT) during heparin
infusion, time between computed tomography
angiographies (CTAs), time from stroke onset
to receiving IV heparin, and vessel occluded
were also compared between groups. Forty-one
patients (19 female, 22 male) were included in
the study with a total of 55 vessels (either
carotid, middle cerebral artery, anterior cere-
bral artery, posterior cerebral artery/posterior
circulation) having intraluminal thrombi; 31
patients had 41 vessels with either partial or
complete recanalization of effected vessels,
while 10 patients had 14 vessels that did not
have at least one vessel recanalize while on
heparin. Using t-test we noted that the average
PTT between the vessels that had partial/com-
plete recanalization group (61.74) and non-
recanalization group (66.30) was not statisti-
cal significantly different (P=0.37).The aver-
age time in days on heparin between vascular
imaging studies (CTA/conventional
angiogram) in the group of vessels with par-
tial/complete recanalization (7.12 days) and
the ones with no change (6.11 days) was not
significantly different between the two groups
(P=0.59). Patient’s vessels receiving heparin
for <24 hours versus those >24 hours did not
significantly differ either (P=0.17). This study
compares patient characteristics associated
with recanalization of intraluminal thrombi in
acute stroke patients on heparin.
Recanalization of intraluminal thrombi are not
associated with average PTT or duration on
heparin. 
Introduction
Meyer and Struzziero described the use of
heparin in acute stroke models in 1958.1 They
administered heparin to monkeys and cats and
observed differences in ischemia and cerebral
circulation. The heparin treated animals
showed that an increase of collateral blood
flow produced more rapid resumption of nor-
mal flow in ischemic areas than in untreated
animals although resulting perivascular hem-
orrhages might be extensive. Although heparin
was likely used in circulation experiments
prior to this study, it was clear that reperfusion
and improved collateral circulation sometimes
came at the cost of reperfusion injury and
bleeding. However, due to the morbidity and
mortality of stroke, heparin and anticoagulants
continued to be an option for acute stroke
treatment from the 1950’s,2 until the develop-
ment and confirmation of efficacy of tissue
plasminogen activator. However, it did not
completely negate the use of anticoagulants in
stroke. The Trial of ORG 10172 (danaparoid) in
Acute Ischemic Stroke Treatment (TOAST)
delineated the need to subtype stroke etiology,
but it was not successful in showing clinical
benefit of a heparinoid in clinical outcomes of
acute stroke patients.3 This study did not
include imaging data including computed
tomography angiography (CTA) or magnetic
resonance angiography (MRA) data as a guide
to determine which patients may benefit from
anticoagulation therapy and advocated these
modalities be used in future studies.3
As mentioned, hemorrhage remains the pri-
mary adverse event that limits heparin use in
acute stroke.4-7 Hemorrhagic conversion of
ischemic brain in stroke patients can be diffi-
cult to manage, especially in stroke patients
who received thrombolytics like intravenous
tissue plasminogen activators.8 Reversing anti-
coagulation after intracranial hemorrhage can
also be a clinical challenge.
A Cochrane Collaborative Review demon-
strated additional lack of evidence of anticoag-
ulation use in acute stroke patients. This
meta-analysis showed that anticoagulation
lowered the chance of recurrent ischemic
stroke but also increased the risk of hemor-
rhage. Subgroup analysis was not performed,
but the authors of this study state that …it is
unclear whether a subgroup of patients who
have strokes in progression with intraluminal
thrombi might benefit from the use of anticoag-
ulation like IV heparin in the acute period fol-
lowing an ischemic stroke. Again, they contend
that the increased risk of hemorrhage pre-
cludes the effective use of anticoagulation in
all acute stroke patients.9 Multiple small stud-
ies and case series have shown utility and
improved outcome as well as recanalization
when using heparin or other anticoagulants in
stroke patients.10-12 But there remain several
questions as to how heparin is able to improve
recanalization. 
Although, recanalization does not necessar-
ily mean clinical improvement, prior studies
imply recanalization is achieved with
heparin.10-12 But, based on its physiology,
heparin should only prevent thrombus propa-
gation. However, it appears to be doing more
than preventing propagation of thrombus. 
This study investigates ischemic stroke
patients who presented with identifiable intra-
arterial thrombi who were administered
heparin and determine if duration of heparin
treatment, partial thromboplastin time (PTT),
location of occlusion, or a particular demo-
graphic of patients was associated with
recanalization.
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Materials and Methods
Institutional review board approval was
granted for a retrospective review of all patient
admissions to a high volume stroke center
where we collected the patient information
including demographic data, of all patients
who were admitted for stroke between May
2006 and September 2011 and were treated
with heparin or heparinoids for intraluminal
thrombi of the carotids or intracranial vessels.
In addition to clinical diagnosis by a neurolo-
gist, imaging studies, either magnetic reso-
nance imaging (MRI) or computed tomogra-
phy perfusion (CTP), computer were used to
confirm that these patients had a stroke, and
CTA or conventional cerebral angiogram was
used to confirm the presence of intraluminal
thrombi by a radiologist. Those patients who
had serial CT angiograms or conventional
angiograms of the carotid and intracranial
large vessels were included in the study for
comparison after heparin administration.
Time between stroke onset and start of
heparin was recorded in hours. A standard IV
heparin protocol was used in all cases and
mean PTT during the heparin administration
was noted. All but one patient was concurrently
on aspirin and/or Plavix. Duration on heparin
and duration between imaging studies were
noted. Radiologists reviewed images for
changes to the intraluminal thrombi of inter-
nal carotids, vertebral, basilar, middle, anteri-
or, and posterior cerebral arteries. These
changes were noted as either complete, par-
tial, or no recanalization by the radiologists. A
neurologist also confirmed these findings. In
order to reduce potential confounding factors
associated with demographic data, vessels
were compared rather than individuals.
Results
A total of 41 patients (22 males, 19 females)
were included in the study, with a total of 55
vessels (28 male vessels, 27 female vessels)
involved (either middle cerebral artery, anteri-
or cerebral artery, posterior cerebral
artery/posterior circulation, or carotids). While
14 patients (7 males, 7 females) had 14 vessels
(7 from male, 7 from female) that had no
recanalization or no change in the intralumi-
nal thrombus of at least one vessel, 31 patients
with 41 vessels (as some patients had multi-
vessel involvement) had complete or partial
recanalization with 20 of those vessels belong-
ing to female patients and 21 belonging to
male patients. However using the Pearson Chi-
Square test, this difference was not statistical-
ly significant between male and female with at
least some recanalization versus no recanal-
ization (Figure 1).  
The mean age between the partial/complete
recanalization group (63.65 years old) and
non-recanalization group (67.8 years old) was
not statistically different using the t-test
(P=0.46). The mean duration on
heparin/heparinoids was 7.12 days for the par-
tial/complete recanalization group (41 vessels)
and 6.11 days for the non-recanalization group
(14 vessels), but there was no statistical differ-
ence between them, using the t-test (P=0.38).
The mean PTT was 61.7 for the partial/com-
plete recanalization group and 66.3 for the
non-recanalization group but again with no
statistical difference between them, again,
using the t-test (P=0.395). Additionally, com-
paring patient’s vessels that were on heparin
for >24 hours versus those <24 hours did not
show a statistical difference in recanalization
(P=0.129) using the Pearson Chi-square test
(Table 1). Although the number of patients
who partially to completely recanalize versus
those that did not was not significant, when
individual locations of vessels were compared
(carotid, MCA, PCA, ACA, and posterior circula-
tion or multi-vessel involvement), the number
of MCA thrombi that partially or completely
recanalized (19 MCA vessels) was significantly
higher than those that did not (2 MCA vessels)
when compared to carotid, while on heparin,
using the Pearson Chi-square test (P=0.014).
However, the other vessels (MCA, ACA, PCA,
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Table 1. Patient age and patient associated heparin infusion data.
                                                                               Recanalization             No          P-value
                                                                                                           recanalization       
Average age (years)                                                                             63.65                           67.80                 0.46
Mean duration on heparin drip (days)                                             7.12                             6.11                  0.68
Mean partial thromboplastin time while on heparin (sec)         61.8                             66.3                  0.18
Number of patients >24 hrs on heparin                                            8                                  3                    0.17
Table 2. Vessel data: median coronary artery recanalization significant compared to
carotid recanalization.
                                                            Vessels            Vessels             Total        P-value
                                                        recanalized  without change     vessels  (Chi-square)
MCA                                                                            19                             2                            21                  0.014
ACA                                                                              4                               0                             4                    0.091
Posterior circulation 
(PCA, basilar, vertebral, AICA, PICA)                  11                             6                            17                  0.547
Carotids                                                                     7                              6                            13                    NA
MCA, median coronary artery; ACA, anterior coronary artery; PCA, posterior coronary artery; AICA, anterior inferior cerebellar artery; PICA;
Figure 1. Flowchart summarizing the result of the study.
basilar, vertebral, and AICA/PICA) were not sta-
tistically significant (Table 2). 
In a logistic regression model comparing the
carotid vessels with the other vessels (i.e.
MCA, ACA, and posterior circulation), showed
an odds ratio (OR) of 3.64 (P=0.058, 95%CI:
0.959 to 13.843) for likelihood of at least some
recanalization with heparin; unfortunately this
was not statistically significant but may indi-
cate a trend. Additional logistic regression
model comparing the MCA vessels with the
carotids, showed an OR=8.14 (P=0.024,
95%CI: 1.32 to 50.25); suggesting heparin may
improve recanalization in MCA vessels better
than in the carotids. The anterior circulation
(MCA and ACA) in comparison to the posterior
circulation (PCA, basilar, vertebral, and
AICA/PICA), demonstrated an OR=6.273
(P=0.04, 95%CI: 1.085 to 36.249) in our logistic
regression model. Of course this data must be
taken in light of a univariate analysis that may
have associated confounding factors that were
able to be accounted for in these models. 
Discussion
As mentioned above, the idea of heparin
improving intracranial stenosis and thrombo-
sis is not new. A study from 1978 showed reso-
lution of cerebral vessel thrombosis after
heparin was given on conventional cerebral
angiogram.10 However, our study does suggest
that intracranial vessels and associated clot
burdens respond to heparin administration
differently. Recanalization leads to improved
outcomes in stroke patients. With large trials,
like CREST and SAMPRIS, showing non-supe-
riority to medical management, it remains
controversial whether mechanical recanaliza-
tion leads to better outcomes than medical
recanalization, especially in patients with
large vessel thrombi. 
Use of any anticoagulation and antiplatelet
agents, are contraindicated in acute stroke
patients receiving TPA in the first 24 hours,
but antiplatelets are initiated after the first 24
hours if no hemorrhage is noted on follow-up
imaging after the first 24 hours. Despite
guideline contra-indicating it, the use of anti-
coagulation in strokes in progression has been
suggested for the last few decades.11-13
Recently there have been reports of use of
antiplatelet agents along with or within the
first 24 hours of giving thrombolytics in stroke
patients.14,15 This remains a controversial
topic but it appears that a select group of
patients may see benefit from earlier initiation
of antiplatelet agents. 
This study demonstrates that for most
stroke patients, anticoagulation is not an effi-
cient mechanism to achieve recanalization.
Duration on heparin, PTT, or demographic
data, did not  significantly associate with com-
plete or partial recanalization. There may
appear to be a difference in heparin’s effect on
recanalization based on the type of vessel
involved, but more likely related to thrombus
characters which was not part of our analysis.
With any study of this size, there is addition-
al unknown confounding data such as prior
use of anti-platelets or anti-coagulation, which
was not collected and multivariate analysis
was not performed. But this was a small study
from a single center using a single IV heparin
protocol. It is noted that almost all patients in
this study were concurrently on antiplatelet
agents, which may improve the efficacy of
heparin effects. Additionally, this study did not
review clinical outcomes of patients, but did
include parameters of heparin administration
and efficacy including average PTT. 
Conclusions
Heparin use in acute stroke patients
remains contraindicated, but there may be a
population of stroke patients who may benefit
from its ability to recanalize intracerebral ves-
sels.  Heparin may not work equally or as effi-
ciently to improve stenosis or occlusions in all
intracranial vessels. Continued study of
heparin or heparinoids in acute stroke
patients should be considered in specific
cases.
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